Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions

Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against Aspergillus fumigatus

(2015) Zaid Al-Nakeeb et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Tissue Penetration of Antifungal Agents

(2014) T. Felton et al.   CLINICAL MICROBIOLOGY REVIEWS

Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B

(2014) V. Strenger et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review

(2014) A. K. Polso et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial

(2014) Eltahir A. G. Khalil et al.   PLoS Neglected Tropical Diseases

Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex

(2013) Rolin L. Wade et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity

(2013) Richard J. Hamill   DRUGS

Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B

(2013) Angela S Loo et al.   Expert Opinion On Drug Safety

Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients

(2013) Lucy O'Connor et al.   JOURNAL OF INFECTIOUS DISEASES

Combination Antifungal Therapy for Cryptococcal Meningitis

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Aerosolized liposomal Amphotericin B: A potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients

(2013) Harutai Kamalaporn et al.   PEDIATRIC PULMONOLOGY

Population Pharmacokinetics of Conventional and Intermittent Dosing of Liposomal Amphotericin B in Adults: a First Critical Step for Rational Design of Innovative Regimens

(2012) William W. Hope et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Experimental Central Nervous System Aspergillosis Therapy: Efficacy, Drug Levels and Localization, Immunohistopathology, and Toxicity

(2012) Karl V. Clemons et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Does Lipid Emulsion Reduce Amphotericin B Nephrotoxicity? A Systematic Review and Meta-analysis

(2012) S. Mistro et al.   CLINICAL INFECTIOUS DISEASES

Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell Recipients

(2011) Gudrun Würthwein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial

(2011) Brad Spellberg et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial

(2011) Shyam Sundar et al.   LANCET

Pharmacokinetics of Liposomal Amphotericin B in Pleural Fluid

(2010) B. Moriyama et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Liposomal Amphotericin B and Echinocandins as Monotherapy or Sequential or Concomitant Therapy in Murine Disseminated and Pulmonary Aspergillus fumigatus Infections

(2010) J. A. Olson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an In Vitro Model of Invasive Pulmonary Aspergillosis

(2010) J. M. Lestner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of 2 Doses of Liposomal Amphotericin B and Conventional Amphotericin B Deoxycholate for Treatment of AIDS‐Associated Acute Cryptococcal Meningitis: A Randomized, Double‐Blind Clinical Trial of Efficacy and Safety

(2010) Richard J. Hamill et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America

(2010) John R. Perfect et al.   CLINICAL INFECTIOUS DISEASES

Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation

(2010) Víctor Monforte et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India

(2010) Shyam Sundar et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel Tropically Stable Oral Amphotericin B Formulation (iCo-010) Exhibits Efficacy against Visceral Leishmaniasis in a Murine Model

(2010) Ellen K. Wasan et al.   PLoS Neglected Tropical Diseases

Comparative Pharmacodynamics of Amphotericin B Lipid Complex and Liposomal Amphotericin B in a Murine Model of Pulmonary Mucormycosis

(2009) R. E. Lewis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Lipid Formulations of Amphotericin B Significantly Improve Outcome in Solid Organ Transplant Recipients with Central Nervous System Cryptococcosis

(2009) Hsin‐Yun Sun et al.   CLINICAL INFECTIOUS DISEASES

Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation

(2009) Hedwig Kolve et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation

(2009) P. Gershkovich et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Temperature-dependent transfer of amphotericin B from liposomal membrane of AmBisome to fungal cell membrane

(2009) Kosuke Shimizu et al.   JOURNAL OF CONTROLLED RELEASE

Nebulized Liposomal Amphotericin B Prophylaxis for Aspergillus Infection in Lung Transplantation: Pharmacokinetics and Safety

(2009) Víctor Monforte et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Treatment of Central Venous Catheter Fungal Infection Using Liposomal Amphotericin-B Lock Therapy

(2009) Bradley S. Buckler et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Efficacy of Single-Dose Liposomal Amphotericin B or Micafungin Prophylaxis in a Neutropenic Murine Model of Invasive Pulmonary Aspergillosis

(2008) R. E. Lewis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of Lipid Amphotericin B Preparations in Treating Murine Zygomycosis

(2008) A. S. Ibrahim et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

(2008) Thomas J. Walsh et al.   CLINICAL INFECTIOUS DISEASES

Aerosolized Liposomal Amphotericin B for the Prevention of Invasive Pulmonary Aspergillosis during Prolonged Neutropenia: A Randomized, Placebo‐Controlled Trial

(2008) Bart J. Rijnders et al.   CLINICAL INFECTIOUS DISEASES

Amphotericin B lipid preparations: what are the differences?

(2008) J.P. Adler-Moore et al.   CLINICAL MICROBIOLOGY AND INFECTION

Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study

(2008) Catherine Cordonnier et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

AMBIZYGO : étude de phase II de l’efficacité d’une posologie initiale élevée d’amphotéricine B liposomale (AmBisome®) [10 mg/kg/j] dans le traitement des zygomycoses

(2008) F. Lanternier et al.   MEDECINE ET MALADIES INFECTIEUSES

Micafungin Versus Liposomal Amphotericin B for Pediatric Patients With Invasive Candidiasis

(2008) Flavio Queiroz-Telles et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL